In a report released today, Andrew Cooper from Raymond James maintained a Buy rating on Haemonetics (HAE – Research Report), with a price target of $76.00. The company’s shares closed last Friday at $66.10.
According to TipRanks.com, Cooper ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -23.5% and a 20.5% success rate. Cooper covers the Healthcare sector, focusing on stocks such as Exact Sciences, NeoGenomics, and QuidelOrtho.
Currently, the analyst consensus on Haemonetics is a Moderate Buy with an average price target of $74.80.
See Insiders’ Hot Stocks on TipRanks >>
Haemonetics’ market cap is currently $3.34B and has a P/E ratio of 77.28.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other. Its products include surgical and diagnostic devices, blood and plasma center devices, blood center software, hospital software, and plasma center software. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Braintree, MA.
Read More on HAE:
- Analysts’ Opinions Are Mixed on These Consumer Goods Stocks: General Mills (GIS), RH (RH) and Enjoy Technology, Inc. (ENJY)
- 3M to Sell Its Neoplast and Neobun Rights to Selic
- United Community Banks, Inc. Announces Date for Second Quarter 2022 Earnings Release and Conference Call
- Fenix Gold EIA Meeting Postponed to July 5, 2022
- Salisbury Bancorp, Inc. Announces 2 For 1 Forward Stock Split
